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A B S T R A C T
We aimed to assess the impact of POLG disease on mental health and quality of life in 15 patients using the
Symptom Checklist-90-R (SCL-90-R) and Short-Form 36 Health Survey (RAND-36). We found increased scores in
all nine subscales of SCL-90-R, particularly phobic anxiety, depression and somatization. Further, patients re-
ported considerably lower scores in all RAND-36 domains. This study revealed a global decline in mental health
and poor quality of life in patients with POLG disease and highlights the need for increased awareness and
systematic assessment in order to improve their quality of life and mental health.
1. Introduction
Mitochondria are essential organelles found in nearly all eukaryotic
cells (Vafai and Mootha, 2012). The most vital role of mitochondria is
to generate ATP via the process of oxidative phosphorylation (OX-
PHOS) (Smeitink et al., 2001), but they are involved in other important
cellular functions including intracellular calcium regulation, phospho-
lipid metabolism and apoptosis (Lu and Claypool, 2015; Green and
Kroemer, 2004). Thirteen of the protein subunits of the OXPHOS system
are encoded by the mitochondrion’s own DNA (mtDNA), while the re-
maining subunits, together with more than a thousand other proteins
required for mitochondrial structure and function are encoded by nu-
clear DNA (nDNA) (Spinazzola and Zeviani, 2009).
Mitochondrial disorders are one of the most common inborn errors
of metabolism with estimated prevalence of 1:5000 (Skladal et al.,
2003). Clinically, affected individuals present a wide spectrum of het-
erogeneous phenotypes that can begin at any age often with multi-
organ involvement. Organs such as brain, skeletal muscles and heart
appear the most vulnerable, but any organ can be affected (Wallace
et al., 2010). Curative treatments are currently lacking and manage-
ment is largely based on symptomatic therapies and maximizing quality
of life (Parikh et al., 2017).
Mitochondrial DNA polymerase γ (Polγ) is the enzyme responsible
for mtDNA replication and repair (Longley et al., 2005). Variants in
POLG, the nuclear gene encoding the catalytic subunit of Polγ, are the
most common cause of inherited mitochondrial disease (Saneto and
Naviaux, 2010) and can be associated with a wide spectrum of clinical
manifestations ranging from devastating fatal neonatal disease to a mild
late onset disease with myopathy and progressive external ophthal-
moplegia(PEO) (Saneto and Naviaux, 2010; Hikmat et al., 2020;
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Hudson and Mitochondrial, 2006). We showed recently that the clinical
spectrum of POLG related disease can be classified into three categories
according to the age of disease onset (Hikmat et al., 2020).
The impact of POLG disease extends beyond the direct effects of
each individual clinical manifestation such as seizures, ataxia or liver
disease, and includes a number of challenges that lead to disability and
reduced quality of life. The chronic and progressive nature of POLG
disease can affect social and psychological well-being as well as phy-
sical health. Individuals with POLG disease may face diminished social
support and family function, cognitive challenges, medical and psy-
chiatric comorbidities, in addition to physical limitations in their daily
activities. Little attention has been given to the psychological burden
and quality of life in patients with mitochondrial diseases including
POLG disease, therefore, the aim of this study was to assess the impact




Individuals were recruited from the national Norwegian POLG
registry (www.polgregister.no) established in 2014 and which includes
almost all individuals with genetically confirmed POLG disease in
Norway. Seventy-four individuals were identified and of these, 26 were
still alive.
Individuals with recessive disease and confirmed biallelic patho-
genic POLG variants or dominant disease and heterozygous confirmed
pathogenic variants, age older than 16 years and able/competent to
provide a written informed consent to participate in the study were
considered eligible. Invitation letter with information about the study,
consent form and study questionnaires were sent by regular post to the
26 potential participants’ home address. Data entry was completed in
June 2019.
2.2. Clinical and genetic data
Clinical and genetic data of individuals who consented to partici-
pate were extracted from the registry. Age of disease onset was defined
by the date of the first symptom(s) requiring medical evaluation. In this
study, we focused on the most frequently reported manifestations of
POLG disease and those which have impact on the morbidity and
mortality (Hikmat et al., 2020; Engelsen et al., 2008). These included:
seizures including status epilepticus, ataxia, stroke like episodes, the
presence of liver impairment defined by the presence of two or more of
the following parameters in at least two different time points - elevated
aspartate aminotransferase (ASAT), gamma-glutamyltransferase (GGT),
bilirubin or ammonia, low serum albumin, or pathological histological
findings of liver biopsy.
Pathogenic POLG variant(s) were identified either by targeted se-
quence analysis (common variants c.1399G > A, p.Ala467Thr and
c.2243G > C, p.Trp748Ser) or by sequence analysis of all coding re-
gions of the POLG gene.
2.3. Mental health
We used the Symptom Checklist-90-R (SCL-90-R) to evaluate mental
health status (Siqveland and Leiknes, 2016). SCL-90-R is a well-vali-
dated and widely used method to evaluate the psychological symptoms
(Derogatis et al., 1973) using a self-reported questionnaire that includes
90 questions covering nine specific areas: bodily ailments, concentra-
tion problems, vulnerability, depression, anxiety, rage, phobia, wor-
rying and alienation. Each of the nine subscales contains 6–13 items.
Items are graded following a five-point Likert-scale of distress, ranging
from “0 = not at all” to “4 = extremely”. The form is well-suited to
measuring general psychological symptoms as well as changes in the
severity. We used the Norwegian manual for administration and the T-
score (Siqveland and Leiknes, 2016). A T-score above 63 is considered
as abnormal and suggests the need for further assessment. In this study,
the time of reference for the symptoms was the previous week.
In addition to the nine symptom-scales described above, SCL-90-R
enables us to measure three global indexes: Global Severity Index (GSI)
is the mean of all respondents’ answers; Positive Symptom Total (PST)
indicates how many times the respondent reports a level of symptom-
score more than 0, and can be interpreted as an expression of symptom
width, the Positive Symptom Distress Index (PSDI) is the mean number
of the questions answered with score more than 0 and can be inter-
preted as an expression of intensity of the reported symptoms
(Siqveland and Leiknes, 2016).
2.4. Health related quality of life (HRQoL)
HRQoL was measured by RAND-36 (Short-Form 36 (SF-36) Health
Survey), which is a generic measure to assess functional health and
well-being in individuals of 14 years of age or older (Ware and
Sherbourne, 1992). This self-reported questionnaire consists of 36 items
and covers eight health domains: physical functioning, bodily pain, role
limitations due to physical health problems, role limitations due to
personal or emotional problems, emotional well-being, social func-
tioning, energy/fatigue, and general health perceptions (Ware and
Sherbourne, 1992). Raw domain-scores are converted to a 0–100 scale,
with lower scores indicating worse HRQoL. (Ware and Sherbourne,
1992; Hays and Morales, 2001). The questionnaire has well docu-
mented validity and reliability, and is widely accepted as a generic
measure of HRQoL in individuals with wide variety of chronic medical
conditions (McHorney et al., 1993, 1994; Paz et al., 2009). Validated
Norwegian version of the RAND-36 was used to evaluate the HRQoL in
individuals with POLG disease in this study. A standard 4 weeks recall
period is applied except for physical functioning and general health,
which pertain to current status. Norwegian normative data of the SF-36
was used for comparative purposes (Garratt and Stavem, 2017).
2.5. Statistics
Demographic and clinical characteristics were reported as numbers
and proportions. Detailed descriptive data analysis was performed on
the entire study cohort using SPSS (Statistical Package of Social
Sciences), Version 25.0. A two-sided P value less than 0.05 was con-
sidered to be statistically significant.
2.6. Ethical statement
All procedures followed were in accordance with the ethical stan-
dards of the responsible committee on human experimentation and
with the Helsinki Declaration of 1975, as revised in 2000. Ethical ap-
proval for the study was obtained from the Regional Committee for
Medical and Health Research Ethics, Western Norway (REK 2014/
1783–4). Signed informed consent was obtained from each patient prior
to enrolment in the study.
3. Results
3.1. Study population
Of the 26 patients who were initially invited, 15 participated in this
study. Ten were females and five males. The median age at disease
onset was 24 years (range = 5–71) and at which the study was con-
ducted was 41 years (range = 16–83). All individuals included in this
study were of Northern European origin.
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3.2. Clinical and genetic findings
The majority of patients had juvenile/adult or late onset disease.
Eight individuals had epilepsy, and seven of these also suffered from
ataxia. Five had had stroke like episodes. Ataxia without epilepsy was
reported in six individuals. Evidence of liver impairment was reported
in two individuals. Four individuals had late onset disease with PEO
and myopathy.
The majority had autosomal recessive disease and were homozygous
or compound heterozygous for common pathogenic founder variants
(c.1399G > A, p.Ala467Thr and c.2243G > C, p.Trp748Ser). Two
individuals had autosomal dominant disease and were heterozygous for
the pathogenic variant c.2864 A > G p.Tyr955Cys.
3.3. Mental health
All nine subscale-scores of SCL-90-R were increased in those parti-
cipating (Table 1). Values ranged from almost abnormal to abnormal
compared to the general population according to the Norwegian
manual for administration and scoring (Siqveland and Leiknes, 2016) .
Global index scores including - Global severity index, positive symptom
total index and positive symptom distress index were all increased as
well.
The three subscales - phobic anxiety (score = 66), depression
(score = 65.7) and somatization (score = 65) had scores above normal
range. Further, no significant differences were observed in the SCL-90-R
subscale-scores when comparing males versus females, those with ju-
venile/ adult versus late onset disease, or those with epilepsy versus
those without.
3.4. Health related quality of life (HRQoL)
Individuals participating in this study reported considerably lower
scores on all RAND-36 domains compared to Norwegian population
norms (Fig. 1, Table 2). Further analyses showed that there were no
statistically significant differences between gender, those with juvenile/
adult or late onset disease, or between those with epilepsy and those
without.
4. Discussion
In the absence of a cure, the main objectives in the management of
patients with mitochondrial disease, including POLG disease, are con-
trol of symptoms, the prevention of complications and improving
quality of life. Data regarding mental health and HRQoL in mitochon-
drial diseases is still limited, but the current study provides the first
comprehensive description of mental health status and the quality of
life in individuals with POLG disease.
Our study clearly identified a global decline in the mental health
status of individuals with POLG disease (Table1). Although there were
no statistically significant differences between the sub-scales of SCL-90-
R, symptoms such as anxiety, depression and somatization were more
frequently reported in patients. The occurrence of psychiatric illness
including major depression, bipolar disorder and panic/anxiety dis-
order has been described previously in individuals with proven mi-
tochondrial disease (Fattal et al., 2006; Suomalainen et al., 1992).
Many descriptions have however, been case reports (Van Goethem
et al., 2003; Luoma et al., 2004; Hakonen et al., 2005) and this study is
the first to describe, in detail, the psychological burden of POLG disease
using patient/self- reported data. We show that, in addition to a large
burden of somatic disease that includes progressive encephalopathy
with cognitive decline and associated episodic disturbances such as in
epilepsy and stroke like episodes (Hikmat et al., 2020; Luoma et al.,
2004; Hakonen et al., 2005; Horvath et al., 2006; Rahman and
Copeland, 2019), patients with POLG disease also have a significant
burden of psychiatric symptoms.
Providing holistic, patient-centred treatment and understanding of
disease burden requires the use of quality of life measures. Quality of
life is a multifaceted concept based on a variety of factors that vary
according to the method of measurement. Components typically in-
clude: physical health, psychological well-being, level of independence,
social relationships, environment and personal beliefs. In the current
study, patient/self-reported data were obtained using the well-vali-
dated RAND-36 (Short-Form 36 Health Survey) questionnaire and then
compared with data obtained from a general Norwegian population.
Our study revealed that POLG disease is associated with a considerably
poorer quality of life (Fig. 1) compared to a general Norwegian popu-
lation (Table2). While a difference of 5–10 points on a 0–100 scale is
generally considered as clinically significant (Fayers, 2007), our study
showed differences of more than 30 points for almost all domains.
Physical and social function and general health domains were even
more impaired. These results show how disabling POLG disease can be
and how it can limit the daily activities, restrict the social interaction
and result in a poorer quality of life.
According to the World Health Organization (WHO), health is de-
fined as, “A state of complete physical, mental and social well-being
and not merely the absence of disease or infirmity”. The WHO devel-
oped a framework, The International Classification of Functioning,
Disability and Health (ICF) for thinking about health in chronic dis-
orders focusing on the biological aspect of human functioning. This
framework comprises four major domains; body function, body struc-
ture, activities and participation and environmental factors. The ICF
framework highlights the importance of using an integrated approach
combining clinical data that in POLG disease includes ataxia, seizures,
muscle weakness, with data reflecting the impact of disease on physical,
social and mental wellbeing.
In the population of patients included in our study, seizures and
ataxia were the most common clinical manifestations, while liver im-
pairment was reported in only two. This reflects the age of patients
recruited to the study. Epilepsy and ataxia are common features in ju-
venile/adult onset disease, while liver impairment is a major feature of
early onset disease (Hikmat et al., 2020). Only one of the individuals
recruited in this study had early onset disease. Further, the majority of
individuals were either homozygous or compound heterozygous of the
common pathogenic founder variants; c.1399G > A, p.Ala467Thr and
c.2243G > C, p.Trp748Ser. This reflects the prevalence of these
founder mutations in Norway (Engelsen et al., 2008; Tzoulis et al.,
2006). Lastly, the sample size making detailed comparisons difficult.
Nevertheless, this study is the first to address the issues of HRQoL and
mental health in POLG disease, and it adds to the existing but limited
data describing the impact of mitochondrial disorders on these para-
meters.
Table 1
Summary of the mental health scores as assessed by SCL-90-R for the
Individuals (N = 15) included in this study (T-Score above 63 is considered
abnormal).
Symptom scale Mean T-score (SD)
Somatization 65.0 (11)
Compulsive symptom 63.9 (12)




Phobic anxiety 66.0 (10)
Paranoid thinking 59.0 (8)
Psychosomatic 59.1 (8)
Global severity index 65.3 (7)
Positive symptom total 61.9 (8)
Positive symptom distress index 66.1 (7)
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5. Conclusion
POLG disease has a clear negative impact on both mental health and
quality of life. We suggest therefore, that systematic assessment of these
parameters should be included in the standard management of these
patients. Involvement of relevant expertise including psychiatrists,
psychologists, occupational therapist and physical therapists in the
management of patients with POLG disease is recommended.
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